[{"id":"b742dbe7-45f3-484c-87c3-e57f6a13cfbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04914351","created_at":"2024-03-13T20:35:51.807Z","updated_at":"2024-07-02T16:35:15.082Z","phase":"Phase 1","brief_title":"HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours","source_id_and_acronym":"NCT04914351","lead_sponsor":"Shanghai HyaMab Biotech Co.,Ltd.","biomarkers":" HLA-E • KLRC1","pipe":"","alterations":" ","tags":["HLA-E • KLRC1"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 11/27/2023","primary_completion_date":" 11/27/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2024-03-13"},{"id":"f0fc99b5-d1de-433b-93c4-9263a9eb22b3","acronym":"BIOREN","url":"https://clinicaltrials.gov/study/NCT03628859","created_at":"2021-01-18T17:49:29.058Z","updated_at":"2024-07-02T16:36:15.363Z","phase":"","brief_title":"BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)","source_id_and_acronym":"NCT03628859 - BIOREN","lead_sponsor":"Centre Leon Berard","biomarkers":" IFNG • IL2RA • CD69 • NCAM1 • IL10 • ENTPD1 • B3GAT1 • ISG20 • KLRC1","pipe":"","alterations":" ","tags":["IFNG • IL2RA • CD69 • NCAM1 • IL10 • ENTPD1 • B3GAT1 • ISG20 • KLRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sunitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-03-15"},{"id":"4e579bc4-0edb-4785-98c5-7919d0eac97b","acronym":"DOMEC","url":"https://clinicaltrials.gov/study/NCT03951415","created_at":"2021-04-01T23:53:05.952Z","updated_at":"2025-02-25T15:08:32.159Z","phase":"Phase 2","brief_title":"Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT03951415 - DOMEC","lead_sponsor":"Leiden University Medical Center","biomarkers":" PD-1 • LAG3 • CTLA4 • CD163 • CD14 • CD68 • ITGAE • KLRB1 • KLRC1","pipe":"","alterations":" ","tags":["PD-1 • LAG3 • CTLA4 • CD163 • CD14 • CD68 • ITGAE • KLRB1 • KLRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2021-04-01"},{"id":"df471fe6-15b5-4ee0-bde3-efd0ed116c02","acronym":"HLA-E CCR","url":"https://clinicaltrials.gov/study/NCT02980146","created_at":"2021-12-29T16:53:33.279Z","updated_at":"2024-07-02T16:37:00.445Z","phase":"","brief_title":"Impact of HLA-E Overexpression by Tumor Cells on the Biology of TIL in Colorectal Cancer","source_id_and_acronym":"NCT02980146 - HLA-E CCR","lead_sponsor":"Nantes University Hospital","biomarkers":" KLRC1","pipe":"","alterations":" ","tags":["KLRC1"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/26/2017","primary_completion_date":" 06/26/2017","study_txt":" Completion: 06/26/2017","study_completion_date":" 06/26/2017","last_update_posted":"2019-04-18"}]